About us new hero

About us

We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.

Read more

Arthur, Oncology Scientist, US

We have 3 global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products.

Our goal is to be one of the world’s most innovative, best performing and trusted healthcare companies.

Our values and expectations are at the heart of everything we do and help define our culture - so that together we can deliver extraordinary things for our patients and consumers and make GSK a brilliant place to work.

Our values are Patient focus, Transparency, Respect, Integrity.
Our expectations are Courage, Accountability, Development, Teamwork.

What we do

We aim to bring differentiated, high-quality and needed healthcare products to as many people as possible, with our 3 global businesses, scientific and technical know-how and talented people.

Pharmaceuticals

Immune system T-cells attacking a cancer cell

Our Pharmaceuticals business has a broad portfolio of innovative and established medicines with commercial leadership in respiratory and HIV. Our R&D approach focuses on science related to the immune system, use of genetics and advanced technologies.

Vaccines

Herpes zoster virus of shingles

Our Vaccines business has a broad portfolio and innovative pipeline of vaccines to help protect people throughout life. We deliver over two million vaccine doses per day to people living in over 160 countries.

Consumer Healthcare

Novamin, a key technology in Sensodyne Repair and Protect

Our Consumer Healthcare business develops and markets an innovative portfolio of consumer preferred and expert recommended brands in the Pain relief, Respiratory, Digestive health, Oral health, Nutrition and Skin health categories.

On 19 December 2018 we announced our agreement with Pfizer to form a new world-leading Consumer Healthcare Joint Venture. Within 3 years of the closing of the transaction, we intend to separate the Joint Venture via a demerger. With our future intention to separate, the transaction also presents a clear pathway forward for us to create a new global Pharmaceuticals/Vaccines company, and a new world-leading Consumer Healthcare company. Find out more

How we do it

Everyone at GSK is focused on 3 priorities – Innovation, Performance, Trust

Innovation

We invest in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients, payers and consumers.

  • £3.9bn

    R&D investment in 2017

  • 3

    major launches in 2017 – Shingrix, a vaccine for shingles, Trelegy Ellipta for COPD and Juluca for HIV

  • £6.7bn

    new product sales in Pharmaceuticals and Vaccines in 2017

  • 13%

    Consumer Healthcare sales in 2017 from product innovations launched over the past three years

Performance

We aim to achieve industry-leading growth by investing effectively in our business, developing our people and delivering flawlessly.
 

  • £30.2bn

    total turnover in 2017

  • £8.6bn

    adjusted operating profit in 2017

  • £3.4bn

    free cash flow in 2017

  • £3.9bn

    dividends paid in 2017

Trust

We are a responsible company and commit to use our science and technology to address health needs, make our products affordable and available and to be a modern employer. 

  • 85%

    of employees proud to work at GSK

  • £261.6m

    donated in 2017 to local communities through product donations, time and cash

  • 1st

    in Access to Medicines Index all 5 times since its launch in 2008

Find out more about us